Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Myelodysplastic Syndromes (MDS) Clinical Trials

A listing of Myelodysplastic Syndromes (MDS) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (290) clinical trials

Anemia is considered to be one of the most prevalent cytopenias in patients who have myelodysplastic syndromes, an umbrella term used to describe disorders relating to the ineffective production of red blood cells, white blood cells, and/or platelets. Ranging in severity from mild (asymptomatic) to severe, anemia can result in ...

Phase

To evaluate the efficacy of romiplostim for the treatment of thrombocytopenia in subjects with MDS Patient Inclusion Criteria: Diagnosis of MDS, 18+ years of age, adequate liver function, written informed consent Patient Exclusion Criteria: Have ever received any disease-modifying treatment MDS, Previously diagnosed with intermediate-2 or high risk MDS using ...

Phase

The purpose of this Study is to evaluate the safety and tolerability of INCB053914 alone and in combination with standard therapies in subjects that have advanced cancer.

Phase

People with Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia are asked to participate in a research study being conducted by Montefiore Medical Center.

Phase N/A

People with Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia are asked to participate in a research study being conducted by Northwell Health.

Phase N/A

Allogeneic hematopoietic stem cell transplantation (aHSCT) can cure patients with a variety of bone marrow failure syndromes (BMFS) including severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH) or myelodysplastic syndrome (MDS) associated with cytopenias. Patients with BMFS have traditionally been transplanted with bone marrow (BM) as a stem cell source. ...

Phase N/A

Background The requirement for licensure became part of the FDA final rules for Human Cells, Tissues, and Tissue-Based Products (HCT/Ps) (March 29, 2004 and May 25, 2005) in an effort to prevent transmission of communicable disease, minimize contamination and preserved integrity and function during processing, outline safety and effectiveness requirements ...

Phase N/A

Severe aplastic anemia (SAA) is a life-threatening bone marrow failure disorder characterized by pancytopenia and a hypocellular bone marrow. Allogeneic bone marrow transplantation offers the opportunity for cure in younger patients, but most are not suitable candidates for transplantation due to advanced age or lack of a histocompatible donor. Comparable ...

Phase N/A

Background The requirement for licensure of human cell and blood products became part of the FDA final rules for Human Cells, Tissues, and Tissue-Based Products (HCT/Ps) (March 29, 2004 and May 25, 2005) in an effort to prevent transmission of communicable disease, minimize contamination and preserved integrity and function during ...

Phase N/A

Severe aplastic anemia (SAA) and myelodysplastic syndrome (MDS) are life-threatening bone marrow disorders. For SAA patients, long term survival can be achieved with immunosuppressive treatment. However, of those patients treated with immunosuppressive therapy, one quarter to one third will not respond, and about 50% of responders will relapse. Combined haplo-cord ...

Phase N/A